Kajiwara Daisuke, Kamoda Hiroto, Yonemoto Tsukasa, Iwata Shintaro, Ishii Takeshi, Tsukanishi Toshinori, Ohtori Seiji, Yamazaki Masashi, Okawa Akihiko
Department of Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan.; Department of Orthopedic Surgery, Chiba University, Chiba, Japan.
Department of Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan.
Asian Spine J. 2016 Jun;10(3):553-7. doi: 10.4184/asj.2016.10.3.553. Epub 2016 Jun 16.
A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4-C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence.
一名43岁的男性C5巨细胞瘤(GCT)患者接受了肿瘤切除及C4 - C6前路骨融合术。术后9个月肿瘤局部复发,患者主诉颈部和肩部疼痛,与术前症状相似。给予地诺单抗治疗,用药两个月后疼痛消失,计算机断层扫描显示肿瘤部位出现硬化边缘形成。对其进行了18个月的随访,无肿瘤复发迹象。一般建议完整切除,但对于许多颈椎GCT患者来说并不容易,因为存在神经血管结构。一些患者会复发,治疗变得更加困难。因此,地诺单抗可能是治疗颈椎复发性GCT的有效选择,尽管需要长期随访以监测是否复发。